Clinical Trial Update: Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, tolerability, and efficacy of ZEP-3Na at two concentrations versus placebo in mild to moderate atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ZEP-3Na

Snippet

Sponsor: Shulov Innovate for Science Ltd. 2012 | Conditions: Atopic Dermatitis | Phase 2 | Status: UNKNOWN